Document is current
Any future updates will be listed below
-
Authors
Boku, Shogen https://orcid.org/0000-0002-5015-0379
Kita, Masato https://orcid.org/0000-0002-0986-5495
Ikoma, Tatsuki https://orcid.org/0000-0003-3758-3425
Yasuda, Tomoyo https://orcid.org/0009-0006-0401-3978
Shibata, Nobuhiro https://orcid.org/0000-0001-8647-5098
Shiraga, Hiroshi https://orcid.org/0009-0001-7261-017X
Butsuhara, Yusuke https://orcid.org/0000-0002-4948-9869
Murata, Hiromi https://orcid.org/0000-0001-9609-0976
Mizokami, Tomomi https://orcid.org/0009-0004-0956-909X
Okada, Hidetaka https://orcid.org/0000-0002-7932-6999
Kanai, Masashi https://orcid.org/0000-0002-6954-4474
- License Information
-
More Information
Article History
Received: 17 November 2025
Accepted: 12 March 2026
First Online: 15 March 2026
Declarations
:
: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of Kansai Medical University Hospital (Approval No. 2025268). The requirement for informed consent was waived by the Institutional Review Board due to the retrospective nature of the study. An opt-out opportunity was provided on the hospital’s website.
: Not applicable as no identifying individual person’s data or images are presented in this manuscript.
: Shogen Boku reports receiving honoraria from MSD K.K. Nobuhiro Shibata reports receiving honoraria from Kyowa Kirin Co., Ltd., MSD K.K., Daiichi Sankyo Company, Limited, and Chugai Pharmaceutical Co., Ltd. Masashi Kanai reports holding unlisted stock in Therabiopharma Co., Ltd. He has also received honoraria from Taiho Pharmaceutical Co., Ltd., AstraZeneca K.K., MSD K.K., and Guardant Health Japan. The other authors have no COI to be disclosed.
